When applied topically, ALOREPAIR topical solution has been shown to stimulate hair growth in individuals with alopecia androgenetica (male pattern baldness).
Although the exact mechanism of action of ALOREPAIR in the treatment of alopecia androgenetica is not known, there may be more than one mechanism by which minoxidil stimulates hair growth; they include: vasodilation of the microcirculation around the hair follicles which may stimulate hair growth;
direct stimulation of the hair follicle cells to enter into a proliferative phase: resting phase (telogen) follicles being stimulated to pass into active phase (anagen) follicles;
alteration of the effect of androgens on genetically predetermined hair follicles: minoxidil may affect the androgen metabolism in the scalp by inhibiting the capacity of androgens to affect the hair follicles.
ALOREPAIR is a topical solution for the treatment of alopecia androgenetica (male pattern baldness of the vertex of the scalp and in females as diffuse hair loss or thinning of the frontoparietal areas). It promotes hair growth and the epithelium of hair bursa.
The response is better when the patients use ALOREPAIR directly after hair loss. At least four months of twice daily applications are generally required before evidence of hair growth can be expected.
If patient respond to treatment, he will need to continue using ALOREPAIR to maintain hair growth. In the treatment of alopecia androgenetica (male-pattern baldness) 1 mL of a 2% or 5% solution of ALOREPAIR is applied twice daily to the scalp. The 5% solution is not recommended for women.
ALOREPAIR is contraindicated in patients with Arterial hypertension, who are hypersensitivity to minoxidil, propylene glycol or ethanol and any other component of the preparation, pregnant and lactating.
Local abrasion or dermatitis of the scalp may increase absorption and hence increase the risk of side effects;
patients with history of or existing heart disease should be advised of potential serious adverse effects;
observing patients for tachycardia and fluid retention;
patients should be monitored for increased heart rate and weight gain or other systemic effects (discontinue use if systemic effects occur);
avoid use in pregnancy, lactation and children below 18 years of age;
avoid contact with eyes and any irritated skin (wash with large amount of water if ALOREPAIR gets into the eyes, mucous membranes or sensitive skin areas).
Do not apply on other parts of the body and stop use when changes in hair colour and texture is noticed.
Avoid co-administration with other topical agents including topical corticosteroids, retinoids, and petrolatum or agents that are known to enhance cutaneous drug absorption.
Avoid administration with guanethidine.
Ask a doctor before use if you have a heart disease.